Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large b-cell lymphoma

American Journal of Clinical Pathology

Volumn 139, Issue 2, 2013, Pages 242-254

  Valentino, Carlo ^a   Kendrick, Samantha ^a   Johnson, Nathalie ^b   Gascoyne, Randy ^c   Chan, Wing C ^d   Weisenburger, Dennis ^d   Braziel, Rita ^e   Cook, James R ^f   Tubbs, Raymond ^f   Campo, Elias ^g   Rosenwald, Andreas ^h   Ott, German ⁱ   Delabie, Jan ^j   Jaffe, Elaine ^k   Zhang, Wenjun ^l   Brunhoeber, Patrick ^l   Nitta, Hiro ^l   Grogan, Tom ^a,l   Rimsza, Lisa ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g HOSPITAL CLÍNIC   (Spain)

^h UNIVERSITY OF WÜRZBURG   (Germany)

ⁱ DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^j OSLO UNIVERSITY HOSPITAL   (Norway)

^k NATIONAL CANCER INSTITUTE   (United States)

^l F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

Colorimetric; Gene expression; Immunohistochemistry; In situ hybridization; Lymphoma; MYC; Ploidy; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MESSENGER RNA; MYC PROTEIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; DNA;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER GENETICS; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 8; COLORIMETRIC IN SITU HYBRIDIZATION; CONTROLLED STUDY; DIPLOIDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE CLUSTER; GENE DOSAGE; GERMINAL CENTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; COLORIMETRY; GENE TRANSLOCATION; GENETICS; LYMPH NODE; METABOLISM; METHODOLOGY; MORTALITY; MULTIGENE FAMILY; ONCOGENE MYC; PATHOLOGY; SURVIVAL RATE; TISSUE MICROARRAY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORIMETRY; CYCLOPHOSPHAMIDE; DNA, NEOPLASM; DOXORUBICIN; GENE DOSAGE; GENES, MYC; HUMANS; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPH NODES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MULTIGENE FAMILY; PREDNISONE; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; SIGNAL TRANSDUCTION; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TRANSLOCATION, GENETIC; VINCRISTINE;

MLCS; MLOWN;

EID: 84875200887     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP2Z0TAGMUYJEB     Document Type: Article

References (26)

1. Slack GW, Gascoyne RD. MYC and aggressive B-cell lymphomas. Adv Anat Pathol. 2011;18:219-228.
2. Jaffe ES. WHO Classification of Tumours, Pathology and Genetics, Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
3. Valera A, Balague O, Colomo L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010;34:1686-1694.
4. Yoon SO, Jeon YK, Paik JH, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008;53:205-217.
5. Stasik CJ, Nitta H, Zhang W, et al. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica. 2010;95:597-603.
6. Testoni M, Kwee I, Greiner TC, et al. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Br J Haematol. 2011;155:274-277.
7. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313-2323.
8. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114:3533-3537.
9. Irizarry RA, Bolstad BM, Collin F, et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31:e15.
10. Johnson NA, Connors JM, Ben-Neriah S, et al. Concurrent expression of MYC and BCL2 in R-CHOP treated diffuse large B cell lymphoma. J Clin Oncol. 2012;30:3452-3459.
11. Rimsza LM, LeBlanc ML, Unger JM, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2008;112:3425-3433.
12. Rimsza LM, Unger JM, Tome ME, et al. A strategy for full interrogation of prognostic gene expression patterns: Exploring the biology of diffuse large B cell lymphoma. PLoS One. 2011;6:e22267.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
14. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28:3360-3365.
15. Choi WWL, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm improves the classification of diffuse large B-cell lymphoma into prognostically significant subgroups. Mod Pathol. 2008;21:250A.
16. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
17. Calcagno DQ, Leal MF, Seabra AD, et al. Interrelationship between chromosome 8 aneuploidy, C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma. World J Gastroenterol. 2006;12:6207-6211.
18. Rayeroux KC, Campbell LJ. Gene amplification in myeloid leukemias elucidated by fluorescence in situ hybridization. Cancer Genet Cytogenet. 2009;193:44-53.
19. Silva TC, Lima PD, Bahia MO, et al. Pisosterol induces interphase arrest in HL60 cells with c-MYC amplification. Hum Exp Toxicol. 2010;29:235-240.
20. Ragheb JW, Yanming Z, Peterson L, et al. Amplification and gain of extra copies of MYC and BCL-2 are common genetic abnormalities in diffuse large B-cell lymphoma (DLBCL) [abstract]. Mod Pathol. 2012;25(suppl 2):381A.
21. Bajor-Dattilo BB, Leung A, Dunleavy K, et al. Correlation of MYC gene translocation status with MYC protein expression in Burkitt lymphoma and diffuse large B cell lymphoma [abstract]. Mod Pathol. 2012;25(suppl 2):324A.
22. Kim H, Yoo SB, Choe JY, et al. Detection of ALK gene rearrangement in non-small cell lung cancer: A comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol. 2011;6:1359-1366.
23. Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, et al. Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH). Diagn Pathol. 2008;3:41.
24. Nitta H, Zhang W, Kelly BD, et al. Automated brightfield break-apart in situ hybridization (ba-ISH) application: ALK and MALT1 genes as models. Methods. 2010;52:352-358.
25. Yoshida A, Tsuta K, Nitta H, et al. Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. J Thorac Oncol. 2011;6:1677-1686.
26. Green TM, Nielsen O, de Stricker K, et al. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol. 2012;36:612-619.